3. What are the goals of pharmacotherapy for this patient?

 Relieving signs and symptoms.

 Long-term improvements of success of therapy.
 Reducing the incidence of agranulocytosis due to antithyroid medication.

Pharmacotherapy principles and practice 3rd edition pdf

6.c. What other interventions would you recommend for this patient?
Consider stopping antithyroid therapy in patients with Grave’s disease after 12-18 months to
see if remission has occurred.

Pharmacotherapy principles and practice 3rd edition pdf

6.d. Develop a monitoring protocol for the pharmacotherapy of hyperthyroidism.

Monitor patient’s antithyroid drugs for signs and symptoms of adverse effects.
 Baseline CBC with differential and liver profile.
 Repeat CBC when patient was a febrile illness. Routine monitoring of WBC is not
recommended.
 Repeat liver panel if signs and symptoms of hepatotoxicity occur (some
recommended routine monitoring during the first six months of therapy.
 Asses any skin rash or development of arthralgia.

Pharmacotherapy principles and practice 3rd edition pdf

6.e. Design a systemic approach for a patient counseling technique for the drug therapy of
hyperthyroidism.
a. Counsel female patients on potential drug-related problems that could occur if taking an ATM while
pregnant or planning on becoming pregnant.
b. Stress the importance of being compliant with therapy
advice patient to keep a record of all clinical laboratory tests and how often they are run.
c. Advice the patient on signs and symptoms of thyroid storm and keep a record of vital signs, especially
blood pressure, heart rate and respiration rate
d. Stress the importance of keeping appointments with one’s primary care physician, ophthalmologist
and endocrinologist.

https://www.uspharmacist.com/article/antithyroid-medications-for-graves-disease